LegalView Informs Mesothelioma Blog Readers of a Predicted Increase in Female Mesothelioma Victims

(PRLEAP.COM) Denver, CO - LegalView reported on its mesothelioma information blog a potential increase of mesothelioma cancer victims within the next few years, particularly among women, according to researchers. In 1979, the U.S. Consumer Product Safety Commission (CPSC) released information regarding 26 companies and manufacturers of hand-held hair dryers that had been made with asbestos. While the 26 companies had voluntarily taken action to correct the asbestos-containing hair dryers, individuals who had used the tainted hair dryers may be at risk for developing mesothelioma and should consider contacting a mesothelioma lawyer for information on the development of a potential mesothelioma lawsuit.

Mesothelioma is a deadly form of lung cancer that is caused through the inhalation of asbestos fibers. Researchers are also particularly concerned for women because women allegedly use hair dryers more than men. To learn more about developing litigation, contact a mesothelioma law firm or mesothelioma attorney to better understand the potential for developing an asbestos-related lawsuit and receiving monetary compensation for the costly bills usually associated with a mesothelioma cancer diagnosis.

In addition to information on mesothelioma, LegalView also offers details on a plethora of other legal issues afflicting millions of Americans each year. For example, readers can learn about the latest fluoroquinolones black box warning labeling. Fluoroquinolones are a group of antibiotics that have become increasingly at risk for severe side effects. Of the fluoroquinolones group, the most commonly prescribed drugs are Levaquin and Cipro. Levaquin, also known as levofloxacin, is manufactured by Ortho-McNeil and treats bacterial infections, specifically treating infections such as skin infections, chronic bacterial prostates, urinary tract infections, pneumonia, bronchitis and acute pyelonephritis caused by Escherichia coli (E. coli). The drug, which was released in 1996, has been the center of numerous clinical trials and studies because of the possible Levaquin side effects , which can include the most serious - Achilles tendon rupture - as well as jaundice, seizures, hallucinations, abdominal tenderness and limb numbness.

Similar to Levaquin is Cipro (ciprofloxacin) from Bayer A.G., which was approved for market use in 2000 and is used to treat bacterial infections similar to those treated by Levaquin. The Cipro risks are the same as Levaquin, which is an increased risk of tendonitis.

LegalView also has information on other controversial prescription drugs including Avandia. Avandia is a type 2 diabetes drug that has recently been linked to severe risks among patients. The Avandia dangers may include an increased risk of heart failure as well as a higher risk of developing early onset osteoporosis. Patients who may have developed either of these side effects while taking Avandia should speak with an experienced pharmaceutical lawyer to better understand the potential for developing a potential Avandia lawsuit .

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation’s most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com’s superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/
Contact Information
Katie Kelley
LegalView.com
720-226-6613
Email LegalView.com

About This News Release

If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.

Share this News
PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy